Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer

Disease Characteristics: * Histologic or cytologic diagnosis or either, colonic, rectal, or breast carcinoma * Measurable lesion diagnosed by CT scan * Recurrent/metastatic disease considered surgically unresectable. Prior/Concurrent Therapy: * Chemotherapy: Patients who either have failed at least one regimen of standard systemic therapy, or are clinically asymptomatic and are not presently being considered for chemotherapy (Enrollment must occur at least 4 weeks beyond last treatment) * Other: Prior treatment with investigational agents is excluded unless follow-up is completed and patient is off study Patient Characteristics/Inclusion Criteria: * Performance Status: Patients with a Karnofsky performance status \> 70% (or equivalent, ECOG 0-1) and expected survival of at least 3 months. * Hematopoietic: WBC \>/= 3000 mm3, neutrophils \>/= 1500 mm3, platelets \>/= 75,000, CEA \< 300 ng/mL * Hepatic: Serum bilirubin \</= 2.0 mg/dL, ALT \< 2.5 x IULN * Cardiovascular: Patients with LVEF \>/= 40% by required MUGA/2D-ECHO study. * Pulmonary: Patients with FEV1 \>/= 60% by required Pulmonary Function Tests * Other: Patients agreeing to use a medically effective method of contraception during and for a period of 3 months after the treatment period. A pregnancy test will be preformed on each premenopausal female of childbearing potential immediately prior to entry into the study. Patients able to understand and give written informed consent. Patients with a significant concurrent medical condition that could affect the patient's ability to tolerate or complete the study.